Marshall Wace
IMMX icon

Marshall Wace’s Immix Biopharma IMMX Stock Holding History

Marshall Wace’s Portfolio IMMX Stock Details IMMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$15M Sell
1,641,552
-337,191
-17% -$2.48M 0.01% 806
2025
Q4 		$10.3M Buy
1,978,743
+1,923,708
+3,495% +$7.92M 0.01% 860
2025
Q3 		$115K Buy
+55,035
New +$132K ﹤0.01% 2640

Other funds holding IMMX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Marshall Wace's IMMX Position: Q1 2026 in Review

Marshall Wace reduced its Immix Biopharma (IMMX) stake by 17% in Q1 2026, selling an estimated $2.48M and leaving 1,641,552 shares worth $15M. The position accounts for 0.01% of the portfolio, ranked #806.

Marshall Wace first reported a position in IMMX in Q3 2025 and has held it in 3 quarters since. 77 funds tracked by Wall St. Rank hold IMMX as of Q1 2026.

  • Marshall Wace held 1,641,552 shares of Immix Biopharma worth $15M as of Q1 2026.
  • Marshall Wace sold 337,191 Immix Biopharma shares in Q1 2026, an estimated $2.48M.
  • Immix Biopharma made up 0.01% of Marshall Wace's portfolio in Q1 2026, its #806 holding.
  • Marshall Wace first reported a position in Immix Biopharma in Q3 2025 and has held it in 3 quarters since.
  • 77 funds tracked by Wall St. Rank held Immix Biopharma as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.